TRIZELL : A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Lung<br/>CancersCancer LocationLung
Cancers

Systemic therapy | LungMesothelioma

Trial Overview Read MoreRead more

This phase 3 trial is evaluating the safety and effectiveness of using a novel gene therapy (rAd-IFN) in combination with an anti-inflammatory drug (Celecoxib) and chemotherapy (Gemcitabine) for the treatment of patients with pleural Mesothelioma.
 

This trial is treating patients with Mesothelioma.

This is a systemic therapy.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.
  • You have had a certain type of treatment or surgical procedure.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma

Commercial Sponsor

Trizell Ltd

Other Non-Commercial Sponsor

University of Pennsylvania

Summary

Patients eligible to participate in this trial will receive either rAd-IFN on the first day of the trial plus celecoxib on Days 1-14 and gemcitabine on days 14 -21 of the treatment cycle, or celecoxib and gemcitabine as described above. Gemcitabine will be received every 3 weeks until the end of the trial.

Recruiting Hospitals Read MoreRead more

Monash Health, Medical Oncology
Clayton
Lung Research Study Coordinator
lung.oncresearch@monashhealth.org

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next